Patents Assigned to Virginia Commonwealth University
  • Patent number: 10102335
    Abstract: Computer-implemented methods for providing improvements in genome-scale metabolic models are described. The methods identify and optimize metabolic flux states that minimize the cost of enzyme production while maximizing a desired cellular phenotype. The computer-implemented methods may maximize cellular phenotypes such as growth (biomass) or production of a metabolite, such as a commercially valuable chemical compound, through the selection of metabolic pathways that maximize these phenotypes while minimizing metabolic costs associated with production of the proteomic constituents of individual metabolic pathways. The computer implemented methods may be useful for computationally designing microbial strains for the production of chemicals.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 16, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Adam Fisher, J. Paul Brooks, Stephen S. Fong
  • Patent number: 10086058
    Abstract: Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 2, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Jason Carlyon
  • Patent number: 10086057
    Abstract: Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 2, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Richard T. Marconi, Lee D. Oliver
  • Patent number: 10077242
    Abstract: Methods of synthesizing the angiotensin II receptor antagonist telmisartan in high yield and purity are provided. The methods involve the coupling of two structurally distinct benzimidazole units via a Suzuki cross-coupling reaction. Methods of regioselectively synthesizing one of the benzimidazole units are also provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: September 18, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Frank Gupton, Alex Martin, Ali Siamaki, Katherine Belecki
  • Publication number: 20180243213
    Abstract: Aerosolized dapsone (or alternatively, an aqueous formulation of dapsone) is used to treat airway inflammation, particularly chronic neutrophil-dominated inflammation. Diseases that may be prevented or treated by the methods include chronic obstructive pulmonary diseases (COPDs), asthma, cystic fibrosis, and others.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 30, 2018
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Bruce K. RUBIN, Soichiro KANOH, Tsuyoshi TANABE
  • Publication number: 20180235907
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Application
    Filed: April 16, 2018
    Publication date: August 23, 2018
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 10046081
    Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 14, 2018
    Assignees: The Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Virginia Commonwealth University
    Inventors: Gary Bowlin, David Simpson, James Bowman, Stephen Rothwell
  • Patent number: 10039815
    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 7, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Jason A. Carlyon
  • Patent number: 10010692
    Abstract: A mixer-heater device provides controllable reduction in aerosol droplet size. Additionally, an intermittent delivery mode for administering an aerosol to a patient may take into account patient expiration and reduce aerosol losses without prolonging treatment time. Depositional losses in aerosol delivery systems may be reduced by streamlining the three dimensional geometry of conduits which change stream direction or flow path diameter. Ventilation systems may also benefit from streamlined components, in particular Y-connectors, with resulting advantages such as reduced rebreathed CO2.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 3, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Philip Worth Longest, Michael Hindle
  • Patent number: 10000453
    Abstract: Chelation directed C—H activation reactions that are catalyzed by Pd(11) on Multi-Walled Carbon Nanotubes (MWCNT), Single-Walled Carbon Nanotubes (SWCNT), or graphene are provided. The reactions are used to directly and regioselectively or regiospecifically functionalize specific C—H bonds, e.g. to build complexity into small molecules. Features and advantages of the present invention will be set forth in the description of invention that follows, and in part will be apparent from the description or may be learned by practice of the invention. The invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: June 19, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Keith C. Ellis, Frank B. Gupton
  • Patent number: 9994865
    Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: June 12, 2018
    Assignees: The Johns Hopkins University, Virginia Commonwealth University
    Inventors: Paul B. Fisher, Swadesh K. Das, Mitchell E. Menezes, Devanand Sarkar, Martin G. Pomper
  • Patent number: 9974758
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: May 22, 2018
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 9957567
    Abstract: Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1 A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein, and packaging containing printed material describing use and indications for the product.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 1, 2018
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, THE PENN STATE RESEARCH FOUNDATION
    Inventors: Janette M McAllister, Jerome F Strauss
  • Patent number: 9951114
    Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: April 24, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Paul B. Fisher, Praveen Bhoopathi, Swadesh K. Das, Luni Emdad, Devanand Sarkar, Upneet Sokhi
  • Patent number: 9951020
    Abstract: A method of making a 2-halonicotinonitrile comprises reacting an alkylidene nitrile with a C1-compound in an organic solvent and a dehydrating agent. The dehydrating agent substantially retards dimerization of the alkylidene nitrile during the reaction. The enamine intermediate that forms from the reaction is cyclized using a halide donor to make the 2-halonicotinonitrile.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: April 24, 2018
    Assignees: Virginia Commonwealth University, The Florida State University Research Foundation, Incorporated
    Inventors: D. Tyler McQuade, Frank B. Gupton, Ashley R. Longstreet, Suzanne M. Opalka
  • Publication number: 20180105562
    Abstract: A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-?B-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 19, 2018
    Applicants: VIRGINIA COMMONWEALTH UNIVERSITY, HEALTH RESEARCH, INC.
    Inventors: Xiang-Yang WANG, Xiaofei YU, John R. SUBJECK
  • Patent number: 9945851
    Abstract: Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 17, 2018
    Assignee: Virginia Commonwealth University
    Inventor: Jason A. Carlyon
  • Patent number: 9943347
    Abstract: An orthopedic implant device and system support the fusion of bones in the medial column of the human foot. An exemplary implant uses an improved lag screw and supplemental components, including a washer plate and transverse screws which penetrate transverse through holes in the shaft of the lag screw. Additionally, a surgical procedure is described which may employ such an implant. The improved lag screw may be inserted at the plantar surface of the first metatarsal and support the fusion of, for example, the transverse tarsal joint, the cuneonavicular joint, and the tarsometatarsal joint.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: April 17, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Jennifer S. Wayne, Robert S. Adelaar, Jacob E. Park, Brian A. Smith
  • Patent number: 9944597
    Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 17, 2018
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, VIRGINIA COMMONWEALTH UNIVERSITY, UNIVERSITY OF RICHMOND
    Inventors: Glen E. Kellogg, Chenxiao Da, Ashutosh Tripathi, John T. Gupton, Nakul Telang, James A. Sikorski, Susan L. Mooberry, Cristina Rohena
  • Patent number: 9931125
    Abstract: Bleeding from blood vessels located in difficult-to-compress regions of the body (especially the abdomen, pelvic or groin region) is controlled by the use of a portable, small-footprint belt-like device that contains multiple inflatable bladders. The inflatable bladders are selectively positioned and inflated over exsanguinating blood vessels, thereby exerting pressure to stop the bleeding. The device may also be used to provide perfusion support in low flow disease states such as hemorrhagic shock and cardiac arrest.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 3, 2018
    Assignee: Virginia Commonwealth University
    Inventors: Kevin Ward, Mark Licata